Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

28
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
28
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

30
Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
30
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.1K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.1K
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

42
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
42
Chronic Pancreatitis I: Introduction01:25

Chronic Pancreatitis I: Introduction

26
Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80%...
26
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

906
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
906

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Annual magnetic resonance cholangiopancreatography surveillance outcomes in individuals with primary sclerosing cholangitis.

Internal medicine journal·2026
Same author

Expert Delphi Consensus on Surrogate Endpoints for Treatment Assessment in Metabolic Dysfunction-associated Steatohepatitis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2025
Same author

Assessment of metabolic dysfunction-associated fatty liver disease in primary care: a consensus statement summary.

The Medical journal of Australia·2025
Same author

Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease-Related Cirrhosis: The ABID-LSM Model.

Alimentary pharmacology & therapeutics·2025
Same author

Rationalising Hepatocellular Carcinoma Screening in Chronic Hepatitis B: Evaluation of Predictive Scores in an Australian Cohort.

Liver international : official journal of the International Association for the Study of the Liver·2025
Same author

Editorial: Crystalising the burden of steatotic liver disease.

Alimentary pharmacology & therapeutics·2024

Related Experiment Video

Updated: May 5, 2026

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.9K

[Nonalcoholic fatty liver disease. A current perspective].

Luis Alberto Pérez Blanco1, Eduardo Vilar Gómez, Yadina Martínez Pérez

  • 1Instituto de Gastroenterología, La Habana, Cuba. luis.perez@infomed.sld.cu

Acta Gastroenterologica Latinoamericana
|December 6, 2013
PubMed
Summary

This review covers updated nonalcoholic fatty liver disease (NAFLD) insights. It details the latest on NAFLD pathophysiology, diagnosis, and management strategies for better patient outcomes.

More Related Videos

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
08:35

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

Published on: May 18, 2021

6.8K
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

1.2K

Related Experiment Videos

Last Updated: May 5, 2026

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.9K
A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
08:35

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

Published on: May 18, 2021

6.8K
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

1.2K

Area of Science:

  • Hepatology
  • Internal Medicine

Context:

  • Nonalcoholic fatty liver disease (NAFLD) is a prevalent chronic liver condition.
  • Increasing global incidence necessitates updated clinical understanding.
  • NAFLD spectrum ranges from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis.

Purpose:

  • To provide a comprehensive review of current NAFLD knowledge.
  • To highlight recent advancements in understanding NAFLD.
  • To consolidate updated diagnostic and management guidelines.

Summary:

  • This review synthesizes recent findings on NAFLD pathophysiology, including genetic and environmental factors.
  • Updated diagnostic approaches are discussed, emphasizing non-invasive methods.
  • Current and emerging management strategies, including lifestyle modifications and pharmacotherapy, are detailed.

Impact:

  • Facilitates a better understanding of NAFLD for clinicians.
  • Supports evidence-based clinical decision-making in NAFLD patient care.
  • Aims to improve patient outcomes through optimized diagnosis and management.